** Medical equipment maker Penumbra PEN.N rise 8.39% to $293.90 in premarket trading
** Revenue rises 10.8% to $315.52 million from a year earlier in fourth quarter; analysts expected $311.52 million, per data compiled by LSEG
** "We expect cash generation to scale nicely in the coming years," analysts at Morgan Stanley say
** J.P.Morgan says "with another year of low-to-mid teens sales growth on tap plus nice margin expansion Penumbra is delivering good fundamental results"
** Of the 19 brokerages covering the stock, at least 14 raised their price targets following the results
** Brokerage Canaccord Genuity raises PT to $340, a Wall Street high, from $323
** Average rating is "buy", with a median PT of $308 - LSEG
** As of last close, stock up ~14% this year; stock fell ~6% in 2024
(Reporting by Joel Jose in Bengaluru)
((joeljose@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.